Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Savara Inc.
Public Company Edition: Apogee grossed $300m and Sagimet raised $85m in the biggest initial public offerings in the US since Acelyrin’s $540m IPO in May. Also, Bausch entered into a $600m funding facility with KKR, Bicycle raised $200m in a FOPO and Caribou garnered $150m from an offering and Pfizer.
Scrip takes a look at key recent drug development activities in the NASH area by Korean firms, which are now pursuing the global development of their candidates as they look to leverage innovation to expand internationally.
Merck’s latest pneumococcal vaccine and Pfizer’s RSV vaccine notched new BTDs, along with Zambon’s inhaled antibiotic for non-CF bronchiectasis, Acer’s vascular Ehlers-Danlos syndrome drug and Dizal’s targeted lung cancer candidate.
Public Company Edition: Instil Bio, Connect Biopharma, Finch Therapeutics, Gain Therapeutics and four heath care-focused SPACs launched initial public offerings; Endo raised $1.3bn via note sale; and Rubius Therapeutics, Solid Biosciences and others priced follow-on offerings.
- Drug Delivery
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Serendex ApS, Mast Therapeutics, Inc.
- SD Pharmaceuticals Inc
- Savara ApS
- Synthrx, Inc.
- Aires Pharmaceuticals, Inc.
- Savara Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.